INVO Fertility, Inc. IVF

Company Overview

INVO Fertility, Inc. is a U.S.-based healthcare and fertility company focused on expanding access to assisted reproductive technology (ART) services. The company operates in the fertility and reproductive healthcare industries and is best known for developing the INVOcell device, an intravaginal culture system designed to facilitate fertilization and early embryo development inside the patient’s body rather than exclusively in a traditional laboratory incubator environment. The company generates revenue through fertility clinic operations, physician partnerships, fertility-related procedures, and sales or licensing associated with its fertility technology platform.

The company’s strategic positioning centers on providing lower-cost fertility treatment alternatives relative to conventional in vitro fertilization (IVF) procedures while expanding fertility care access in underserved markets. INVO Fertility evolved from a medical device-focused business into an operator and partner of fertility clinics through acquisitions, clinic investments, and physician collaborations. Public disclosures, including SEC filings and investor materials, indicate that the company has increasingly emphasized clinic ownership and operational integration as part of its long-term growth model.

Business Operations

INVO Fertility’s operations primarily consist of fertility clinic management, fertility treatment services, and commercialization of the INVOcell technology platform. The company has operated through fertility center ownership interests, partnerships with reproductive endocrinologists, and affiliated clinic entities. Revenue is generated from fertility consultations, IVF and related ART procedures, laboratory services, and fertility treatment cycles conducted through affiliated centers. The company has also pursued recurring revenue opportunities tied to physician networks and clinic expansion.

Operationally, the company has focused on building a network of fertility centers in the United States while evaluating opportunities for broader international commercialization. Publicly disclosed assets include ownership interests or affiliations with fertility clinics and fertility care brands such as INVO Centers. The company has collaborated with fertility specialists and healthcare providers to expand treatment availability and integrate its intravaginal incubation technology into clinical workflows. Data regarding the scale of international operations remains limited in public filings, and some operational details are inconclusive based on available public sources.

Strategic Position & Investments

INVO Fertility’s strategy has emphasized expanding affordable fertility care access through clinic acquisitions, partnerships, and broader utilization of the INVOcell platform. The company has publicly identified growth initiatives involving additional fertility center development, increased patient accessibility, and vertical integration across fertility treatment services. Management communications and regulatory filings indicate that the company views lower-cost fertility alternatives as a differentiator within the broader ART market.

The company has pursued investments in fertility clinic infrastructure and ownership interests in reproductive healthcare operations. Strategic efforts have included acquisitions and partnerships intended to increase geographic reach and patient volume. INVO Fertility has also positioned itself within emerging healthcare trends focused on decentralized fertility treatment delivery and broader affordability in reproductive medicine. While the company has discussed future expansion opportunities, some forward-looking operational outcomes cannot be independently verified from currently available public information.

Geographic Footprint

INVO Fertility is headquartered in the United States and primarily operates within the U.S. fertility healthcare market. The company’s activities have included fertility center operations and partnerships across multiple U.S. regions, with strategic emphasis on expanding access to fertility care domestically. Public disclosures identify clinic operations and affiliated services in selected metropolitan markets where demand for reproductive healthcare services is growing.

The company has also pursued international awareness and commercialization opportunities for the INVOcell technology platform through distribution relationships and regulatory clearances outside the United States. Public information indicates interest in broader international market participation, although the company’s direct operational footprint outside North America appears limited relative to larger global fertility providers. Data regarding the scale of international revenue contribution is inconclusive based on available public sources.

Leadership & Governance

INVO Fertility is led by executives with backgrounds in healthcare operations, medical technology, and fertility services. Leadership strategy has focused on expanding clinic ownership, increasing patient affordability, and scaling fertility treatment access through integrated reproductive healthcare operations. The company’s governance structure follows public company reporting standards through filings with the U.S. Securities and Exchange Commission.

Key executives identified in recent public filings and investor disclosures include:

• Steve Shum – Chief Executive Officer
• Andrea Goren – Chief Financial Officer
• Dr. Gerald L. Joyce – Chief Medical Officer

Leadership communications in SEC filings and investor presentations have consistently emphasized operational expansion, fertility care accessibility, and long-term growth through clinic network development and technology-enabled reproductive healthcare services.